Depomed To Report First Quarter Fiscal Year 2013 Financial Results On Wednesday, May 8, 2013

    Depomed To Report First Quarter Fiscal Year 2013 Financial Results On
                            Wednesday, May 8, 2013

PR Newswire

NEWARK, Calif., May 1, 2013

NEWARK, Calif., May 1, 2013 /PRNewswire/ --Depomed, Inc. (NASDAQ:DEPO) today
announced that it will release first quarter fiscal year 2013 financial
results after the market closes onWednesday, May 8, 2013. The Company will
host a conference call beginning at 4:30 pm Eastern time,1:30
pmCaliforniatime to discuss its results.

Participants can access the call by dialing 877-317-6789 (United States) or
412-317-6789 (international). The conference call will also be available via a
live webcast on the investor relations section of Depomed's website at Access the website 15 minutes prior to the start of
the call to download and install any necessary audio software. An archived
webcast replay will be available on the Company's website for three months.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with three approved and
marketed products. Gralise® (gabapentin) is a once-daily treatment approved
for the management of postherpetic neuralgia (PHN). Zipsor ® (diclofenac
potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug
(NSAID) indicated for relief of mild to moderate acute pain in adults.
Glumetza® (metformin hydrochloride extended release tablets) is approved for
use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in
the United States. Depomed formulates its products and product candidates with
its proven, proprietary Acuform® drug delivery technology, which is designed
to improve existing oral medications, allowing for extended release of
medications to the upper gastrointestinal tract when dosed with food.
Additional information about Depomed may be found on its website,

August J. Moretti
Depomed, Inc.

SOURCE Depomed, Inc.

Press spacebar to pause and continue. Press esc to stop.